Colloidal P-32 Chromic Phosphate is administered via which route?

Colloidal P-32 Chromic Phosphate is administered via which route?

• A. Intravenous
• B. Subcutaneous
• C. Intramuscular
• D. Intraperitoneal

Answer: (D)

Colloidal P-32 Chromic Phosphate is administered intraperitoneally. This route is particularly effective for targeting specific abdominal malignancies, such as peritoneal carcinomatosis. When injected into the peritoneal cavity, the radioactive colloid disperses throughout the space, allowing for localized radiation therapy to tumor sites while minimizing exposure to surrounding healthy tissues. This method takes advantage of the unique properties of P-32, which is a beta-emitting isotope that can provide a therapeutic effect directly where it is needed most, within the abdominal cavity. Its administration is aimed at achieving a higher concentration of the radioactive material at the tumor sites, thereby enhancing its efficacy in treating certain forms of cancer. Other routes such as intravenous, subcutaneous, or intramuscular would distribute the radioactive agent systemically, which would not provide the same localized therapeutic effect and could lead to undesired side effects in non-target areas of the body. Thus, the intraperitoneal route is specifically chosen for this type of treatment.

Colloidal P-32 Chromic Phosphate is administered intraperitoneally. This route is particularly effective for targeting specific abdominal malignancies, such as peritoneal carcinomatosis. When injected into the peritoneal cavity, the radioactive colloid disperses throughout the space, allowing for localized radiation therapy to tumor sites while minimizing exposure to surrounding healthy tissues.

This method takes advantage of the unique properties of P-32, which is a beta-emitting isotope that can provide a therapeutic effect directly where it is needed most, within the abdominal cavity. Its administration is aimed at achieving a higher concentration of the radioactive material at the tumor sites, thereby enhancing its efficacy in treating certain forms of cancer.

Other routes such as intravenous, subcutaneous, or intramuscular would distribute the radioactive agent systemically, which would not provide the same localized therapeutic effect and could lead to undesired side effects in non-target areas of the body. Thus, the intraperitoneal route is specifically chosen for this type of treatment.